BLOOM BURTON&CO reiterated their hold rating on shares of ProMetic Life Sciences Inc. (TSE:PLI) in a report issued on Thursday morning.
A number of other equities research analysts also recently weighed in on the company. Scotiabank reaffirmed an outperform rating and set a C$5.00 price objective on shares of ProMetic Life Sciences in a research report on Tuesday, August 16th. Royal Bank Of Canada reaffirmed an outperform rating on shares of ProMetic Life Sciences in a research report on Wednesday, June 15th. TD Securities reaffirmed a speculative buy rating and set a C$4.50 price objective on shares of ProMetic Life Sciences in a research report on Wednesday, September 28th. Finally, CIBC dropped their price objective on ProMetic Life Sciences from C$5.00 to C$4.85 in a research report on Thursday, August 25th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. ProMetic Life Sciences has a consensus rating of Buy and a consensus target price of C$4.84.
ProMetic Life Sciences (TSE:PLI) remained flat at $3.10 during midday trading on Thursday. 131,216 shares of the stock traded hands. The stock’s market cap is $1.87 billion. ProMetic Life Sciences has a 52-week low of $1.67 and a 52-week high of $3.62. The company’s 50 day moving average price is $2.93 and its 200-day moving average price is $3.01.